Showing 1 - 10 of 45 results

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. The two companies will leverage their combined scientific, commercial and market…

Smart. Simple. Complete. GE Healthcare's Latest Innovations in Cancer Care on Display at ASTRO 2014

Multidisciplinary solutions to help integrate planning and improve quantitation and efficiency in radiation oncology SAN FRANCISCO, CALIFORNIA -- September 15, 2014 -- GE Healthcare, a division of…

GE Announces Commitments to Improve Cancer Care in Ethiopia

Addis Ababa, Ethiopia -- 6 August 2014 -- Building on a growing footprint in Ethiopia and commitment to supporting the priorities of Ethiopia's public and private healthcare providers, GE today…

GE Healthcare Announces Norwegian Medicines Agency Approval of Sonazoid™ (powder and solvent for dispersion for injection) to Detect Liver Lesions

Oslo, Norway -- May 2014 -- GE Healthcare today announced the Norwegian Medicines Agency's (NOMA) approval of SonazoidTM (powder and solvent for dispersion for injection), a contrast agent for use in…

Personalized Care from Disease Detection through Treatment Assessment Enabled with GE Healthcare's Discovery IQ

ST. LOUIS -- Today at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery* IQ^ PET/CT system, enabling both outstanding image quality…

GE Healthcare Announces FDA Approval of Invenia™ Automated Breast Ultrasound System (ABUS) for Enhanced Patient Experience and More Accurate Diagnosis than Mammography alone in women with Dense Breasts

First U.S. Installs of Next-generation Breast Imaging Technology at Fairfax Radiological Breast Diagnostic Imaging Center in DC and Phelps Memorial Hospital in NYMILWAUKEE, WI -- 3 June 2014 -- GE…

GE Healthcare Announces FDA Approval to Supply Technetium 99m Generators

Princeton, NJ -- May 30, 2014 -- Effective from June 1st 2014 and following approval by the US Food and Drug Administration (FDA), GE Healthcare today announced the intent to supply generators for…

Fast, High Definition, Low Dose: GE Healthcare Announces FDA Clearance of Revolution CT

System converges best capabilities of spatial resolution, temporal resolution, whole organ coverage to enable physicians to diagnose even the most challenging patientsWAUKESHA, Wisc. -- GE Healthcare…

New Studies Show How Using GE Healthcare's MultiOmyx™ in Hodgkin Lymphoma and Breast Cancer Cases May Improve Disease Assessment

Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer ALISO VIEJO, CA, December 9, 2013 -- GE Healthcare today announced results from two studies that show…

Developing World Faces Breast Cancer Surge, Study Suggests

* Consumer awareness and cultural barriers surrounding screening putting lives at risk* 15 million years of 'healthy life' were lost worldwide in 2008 due to women dying early or being ill with the…